Evidence map›Paper›PMID 42140989›Full record

ReviewNPJ breast cancer2026

Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.

Caterina Marchiò, Federico Rojo, Ellen R Copson, Fernando Schmitt, Beatriz Bellosillo, Carlo Fremd

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caterina Marchiò *Pathology Unit, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Italy. caterina.marchio@unito.it.
Federico Rojo *Pathology Department, IIS-Fundacion Jimenez Diaz University Hospital-CIBERONC-UAM, Madrid, Spain.
Ellen R Copson *School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Fernando Schmitt *RISE-Health, Department of Pathology, Medical Faculty of University of Porto, Porto, Portugal.
Beatriz Bellosillo *Pathology Department, Hospital del Mar Research Institute-CIBERONC-University Pompeu Fabra, Barcelona, Spain.
Carlo Fremd *Department of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ, the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thorax Clinic Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PIK3CA mutations are common in HR+/HER2- metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.

Identifiers

PMID42140989
PMCPMC13433983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.